Dateline City:
ZURICH
KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival
Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress
ZURICH--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that a pre-specified analysis of investigational data
from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, substantially improved
the primary endpoint of progression-free survival (PFS, as assessed by
RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg
and 10 mg/kg every three week doses, respectively), compared to
chemotherapy (P<0.0001 for both comparisons)
Language:
English
Contact:
MerckMedia:Lainie Keller, 908-236-5036Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more